1
|
Sun T, Mei N, Su Y, Shan S, Qian W, Li M, Zhang Z. Mendelian randomization combined with multi-omics explores the relationship between heart failure and cancer. J Cancer 2024; 15:2928-2939. [PMID: 38706896 PMCID: PMC11064263 DOI: 10.7150/jca.94142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 02/27/2024] [Indexed: 05/07/2024] Open
Abstract
Background: Whether there is an association between HF (HF) and cancer has not been conclusively established, and it is not clear whether patients with cancer can share similar hospitalization strategies and outcomes with patients with HF. Methods: Genome-wide association summary statistics were performed using a two-sample Mendelian randomization (MR) method for HF patients and cancer patients from the GWAS directory, with co-localization and Summary Data-Based Mendelian Randomization (SMR) analyses to identify HF-associated genes, and transcriptomic analyses to analyze the roles of these genes in the clinical diagnosis and targeted therapies of multiple cancer types. Results: Two-sample MR analysis showed that increased risk of HF was associated with decreased risk of cervical, brain, breast, colorectal, lung, and skin cancers, and co-localization combined with SMR analysis identified ABO and SURF1 as HF-associated genes, and transcriptomic analyses showed that ABO is a risk factor for HF and a protective factor against cancer, whereas SURF1 is a protective factor against HF and a protective factor against cancer. Conclusion: There was no causal relationship between heart failure and cancers (Cervical, brain, breast, colorectal, lung and skin cancers) risk factors, however there was a trend toward a negative causal relationship between heart failure and cancers (Cervical, brain, breast, colorectal, lung and skin cancers) occurrence.
Collapse
Affiliation(s)
- Tian Sun
- Hubei provincial key laboratory of diabetic cardiovascular diseases, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
- School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Na Mei
- Hubei provincial key laboratory of diabetic cardiovascular diseases, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Yanting Su
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Shigang Shan
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Wenbin Qian
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Mengxi Li
- School of Nuclear Technology and Chemistry & Biology, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| | - Zhenwang Zhang
- Hubei provincial key laboratory of diabetic cardiovascular diseases, Xianning Medical College, Hubei University of Science and Technology, Xianning 437100, Hubei, People's Republic of China
| |
Collapse
|
2
|
Jhatta C, Girdhar J, Gupta S, Verma I. To Compare the Level of Cystatin C in Type 2 Diabetes Mellitus with Obesity. Indian J Endocrinol Metab 2020; 24:312-318. [PMID: 33088753 PMCID: PMC7540831 DOI: 10.4103/ijem.ijem_408_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Revised: 07/08/2020] [Accepted: 07/09/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Cystatin C is a non-glycosylated basic protein that is produced and secreted at a constant rate by all nucleated cells. Cystatin C is a more reliable marker than the serum creatinine because it is less affected by external factors such as gender, race and muscle mass. However, the comparison of serum cystatin C level in type 2 diabetes mellitus is not well known in people with obesity. OBJECTIVES To estimate the level of cystatin C in type 2 diabetes and that can be explained by the change in obesity. Thus, this current study aimed to determine and compare the level of cystatin C in type 2 DM with obesity and also correlate the cystatin C level with the quality of life in type 2 DM and obesity. MATERIAL AND METHODS We have taken three groups: Group A containing type 2 DM, Group B containing obesity, and Group C containing type 2 DM with obesity. In all, 25 patients in each group were selected and analyzed for cystatin C. RESULTS Cystatin C level was very high in type 2 DM with obesity group. The P value was 0.008 in type 2 DM with the obesity group and it has shown a highly significant correlation with BMI. In our study, we have also seen the positive correlation of cystatin C with BMI in Group B plain obese and Group C diabetes obese than Group A diabetes non-obese. We have seen in our study and found a poor correlation between HbA1c, RBS and cystatin C. CONCLUSION The level of cystatin C is much higher in type 2 DM with obese patient as compared with type 2 DM and obese patients.
Collapse
Affiliation(s)
- Chahat Jhatta
- Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India
| | - Jashan Girdhar
- Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India
| | - Sumeet Gupta
- Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India
| | - Inderjeet Verma
- Department of Pharmacy Practice, MM College of Pharmacy, Maharishi Markandeshwar Deemed to be University, Mullana, Ambala, Haryana, India
| |
Collapse
|
3
|
Funamoto M, Shimizu K, Sunagawa Y, Katanasaka Y, Miyazaki Y, Komiyama M, Yamakage H, Satoh-Asahara N, Takahashi Y, Wada H, Hasegawa K, Morimoto T. Serum Cystatin C, a Sensitive Marker of Renal Function and Cardiovascular Disease, Decreases After Smoking Cessation. Circ Rep 2019; 1:623-627. [PMID: 33693109 PMCID: PMC7897701 DOI: 10.1253/circrep.cr-19-0052] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 10/18/2019] [Accepted: 10/27/2019] [Indexed: 12/23/2022] Open
Abstract
Background: Smoking exerts detrimental effects during the progression of atherosclerotic vascular disease. Serum cystatin C is useful in the evaluation of early renal dysfunction and serves as a cardiovascular prognostic marker. This study measured changes in serum cystatin C after smoking cessation (SC). Methods and Results: In this study, patients who visited the SC clinic for the first time and succeeded in SC for 1 year were enrolled. In the entire cohort of 86 patients, body mass index (BMI, P<0.001) and waist circumference (WC, P<0.001) increased significantly at 3 months after SC compared with baseline. These values were further increased significantly (BMI, P<0.001; WC, P<0.001) from 3 months to 1 year after SC. Serum cystatin C decreased significantly at 3 months (P=0.045) after SC, and remained unchanged (P=0.482) from 3 months to 1 year after SC. Percent change from baseline to 3 months after SC in serum cystatin C was correlated with the percent change in serum monocyte chemoattractant protein 1 (P=0.047). Conclusions: Serum cystatin C, a marker of chronic kidney disease, was significantly reduced at 3 months after SC.
Collapse
Affiliation(s)
- Masafumi Funamoto
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Kana Shimizu
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Yoichi Sunagawa
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Yasufumi Katanasaka
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Yusuke Miyazaki
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Maki Komiyama
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Hajime Yamakage
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Noriko Satoh-Asahara
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Yuko Takahashi
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Hiromichi Wada
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Koji Hasegawa
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| | - Tatsuya Morimoto
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka Shizuoka Japan
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center Kyoto Japan
| |
Collapse
|